Compass Pathways is a mental health care company developing new treatments for people who haven’t responded to existing medications and continue to struggle with their mental health. The company was the first to report successful Phase 3 clinical trial results for a psychedelic treatment, known as COMP360 psilocybin, for treatment-resistant depression (TRD) and is positioned to potentially be the first to receive regulatory approval and bring a psychedelic-based medicine to market.

Kabir Nath, the CEO of Compass Pathways, details his company's path building a scalable, safe, and accessible psychedelic care system and model. Kabir speaks with Carol Massar and Alexis Christoforous on Bloomberg Businessweek Daily.